STOCK TITAN
  1. Home
  2. Financials
  3. DMII

Drugs Made In Amer Acq Ii Corp Financials

DMII
Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Drugs Made In Amer Acq Ii Corp (DMII) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DMII FY2025

Balance-sheet redeployment, not operating activity, defines this company: capital raised was pushed into assets while the core entity stayed minimal.

The combination of $4.2M in net income, an operating loss, and -$1.0M of operating cash flow suggests reported profit came from non-operating balance-sheet effects rather than a business that turns activity into cash. With $505.0M of assets against $522.7M of liabilities, that accounting profit sits on a capital structure where modest balance-sheet shifts can outweigh operating results.

Cash movements look transaction-driven: $501.0M of financing inflow was almost matched by $500.0M of investing outflow, so the entity behaved more like a funded pool of assets than an operating company deploying retained cash or internally generated funds.

Short-term liquidity is extremely thin; a current ratio of 0.1x alongside just $223 of cash means near-term obligations are not covered by readily available resources inside the entity. Negative equity also means creditor claims exceed book assets, so solvency is being carried by structure and funding arrangements rather than accumulated earnings.

Generated by Rhea from SEC filings [ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score pending refresh

We are recalculating Drugs Made In Amer Acq Ii Corp's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Earnings Quality Low Quality
-0.24x

For every $1 of reported earnings, Drugs Made In Amer Acq Ii Corp generates $-0.24 in operating cash flow (-$1.0M OCF vs $4.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
N/A
EBITDA
N/A
Net Income
$4.2M

Drugs Made In Amer Acq Ii Corp reported $4.2M in net income in fiscal year 2025.

EPS (Diluted)
N/A

Cash & Balance Sheet

Free Cash Flow
N/A
Cash & Debt
$223

Drugs Made In Amer Acq Ii Corp held $223 in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
66M

Drugs Made In Amer Acq Ii Corp had 66M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Return on Equity
N/A

Capital Allocation

R&D Spending
N/A
Share Buybacks
N/A
Capital Expenditures
N/A

DMII Income Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24
Revenue N/A N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A N/A
Gross Profit N/A N/A N/A N/A N/A N/A
R&D Expenses N/A N/A N/A N/A N/A N/A
SG&A Expenses $132K N/A $156K N/A $59K-60.9% $152K
Operating Income -$132K N/A -$156K N/A -$59K+60.9% -$152K
Interest Expense N/A N/A N/A N/A N/A N/A
Income Tax N/A N/A N/A N/A N/A N/A
Net Income $4.3M N/A -$46K-21.2% -$38K+35.8% -$59K+60.9% -$152K
EPS (Diluted) $0.07 N/A N/A N/A N/A N/A

DMII Balance Sheet

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24
Total Assets $509.7M+0.9% $505.0M+0.8% $501.0M N/A N/A $138K
Current Assets $352K+1251.0% $26K-97.1% $896K N/A N/A $60K
Cash & Equivalents $348K+155828.3% $223-99.9% $315K N/A $7K-59.0% $17K
Inventory N/A N/A N/A N/A N/A N/A
Accounts Receivable N/A N/A N/A N/A N/A N/A
Goodwill N/A N/A N/A N/A N/A N/A
Total Liabilities $527.5M+0.9% $522.7M+0.9% $518.3M N/A N/A $255K
Current Liabilities $666K+121.5% $301K-55.6% $677K N/A N/A $255K
Long-Term Debt N/A N/A N/A N/A N/A N/A
Total Equity -$17.8M-0.2% -$17.8M-2.9% -$17.3M-7970.7% -$214K-21.6% -$176K-50.8% -$117K
Retained Earnings -$17.8M-0.2% -$17.8M-2.9% -$17.3M N/A N/A -$152K

DMII Cash Flow Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24
Operating Cash Flow -$103K+67.4% -$315K N/A N/A -$10K+94.8% -$194K
Capital Expenditures N/A N/A N/A N/A N/A N/A
Free Cash Flow N/A N/A N/A N/A N/A N/A
Investing Cash Flow N/A $0 N/A N/A N/A N/A
Financing Cash Flow $450K $0 N/A N/A N/A $211K
Dividends Paid N/A N/A N/A N/A N/A N/A
Share Buybacks N/A N/A N/A N/A N/A N/A

DMII Financial Ratios

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24
Gross Margin N/A N/A N/A N/A N/A N/A
Operating Margin N/A N/A N/A N/A N/A N/A
Net Margin N/A N/A N/A N/A N/A N/A
Return on Equity N/A N/A N/A N/A N/A N/A
Return on Assets 0.9% N/A -0.0% N/A N/A -109.9%
Current Ratio 0.53+0.4 0.09-1.2 1.32 N/A N/A 0.23
Debt-to-Equity -29.61-0.2 -29.41+0.6 -29.99 N/A N/A -2.18
FCF Margin N/A N/A N/A N/A N/A N/A

Note: Shareholder equity is negative (-$17.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.09), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

Yes, Drugs Made In Amer Acq Ii Corp (DMII) reported a net income of $4.2M in fiscal year 2025.

Drugs Made In Amer Acq Ii Corp (DMII) generated -$1.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Drugs Made In Amer Acq Ii Corp (DMII) had $505.0M in total assets as of fiscal year 2025, including both current and long-term assets.

Drugs Made In Amer Acq Ii Corp (DMII) had 66M shares outstanding as of fiscal year 2025.

Drugs Made In Amer Acq Ii Corp (DMII) had a current ratio of 0.09 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Drugs Made In Amer Acq Ii Corp (DMII) had a debt-to-equity ratio of -29.41 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Drugs Made In Amer Acq Ii Corp (DMII) had a return on assets of 0.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Drugs Made In Amer Acq Ii Corp (DMII) had $223 in cash against an annual operating cash burn of $1.0M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Drugs Made In Amer Acq Ii Corp (DMII) has negative shareholder equity of -$17.8M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Drugs Made In Amer Acq Ii Corp (DMII) has an earnings quality ratio of -0.24x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top